864266-28-4

Basic information

• Product Name: (Z)-6-bromonicotinaldehyde oxime
• Synonyms: (Z)-6-bromonicotinaldehyde oxime;6-bromonicotinaldehydeoxime;6-Bromo-pyridine-3-carbaldehyde oxime
• CAS NO: 864266-28-4
• Molecular Formula: C₆H₅BrN₂O
• Molecular Weight: 201.023
• Mol File: 864266-28-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (Z)-6-bromonicotinaldehyde oxime(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-6-bromonicotinaldehyde oxime(864266-28-4)
• EPA Substance Registry System: (Z)-6-bromonicotinaldehyde oxime(864266-28-4)

Safety Data

• Hazardous Substances Data: 864266-28-4(Hazardous Substances Data)

Usage

General Description

(Z)-6-bromonicotinaldehyde oxime is a chemical compound that is primarily used in the field of organic chemistry and drug development. It is an oxime derivative of (Z)-6-bromonicotinaldehyde, which is a precursor in the synthesis of various organic compounds. This chemical has been studied for its potential biological activities, including its anti-cancer and anti-inflammatory properties. Additionally, (Z)-6-bromonicotinaldehyde oxime has also been investigated for its potential use as a chelating agent in metal ion coordination chemistry. Overall, this compound has shown promise in various research fields and continues to be studied for its potential applications.

Upstream product

• 149806-06-4 6-bromonicotinaldehyde 
• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 

Downstream Products

• 139585-70-9 2-bromo-5-cyanopyridine 

Relevant articles and documents

Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model

The aryl hydrocarbon receptor (AhR), a ligand-dependent transcription factor, can regulate the immune balance of Th17/22 and Treg cells, which plays an important role in the development and maintenance of the skin barrier. We herein report the discovery of triazolopyridine derivatives as a new class of AhR agonists. Structure-activity relationship analyses led to the identification of the most active compound, 6-bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine (12a), with an EC50 (50% effective concentration) value of 0.03 nM. Compound 12a could induce rapid nuclear enrichment of AhR, trigger the transcription of downstream genes and promote skin barrier repair. Topical or oral administration of 12a could significantly alleviate imiquimod (IMQ)-induced psoriasis-like skin lesion. Considering the excellent in vivo anti-psoriasis activity as well as good pharmacokinetic properties, 12a could be a promising lead compound for drug discovery against psoriasis, and deserving further investigation.

Synthesis of Novel 3-aryl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Derivatives and Their Biological Evaluation Against Protein Tyrosine Phosphatase 1B

A series of novel 3-aryl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene derivatives were designed, synthesized, and evaluated as a new class of inhibitors against protein tyrosine phosphatase 1B. Among them, compound 6f displayed moderate inhibitory activity with IC50 of 2.87 ± 0.24 μm and can be used as a novel lead compound for the design of inhibitors of protein tyrosine phosphatase 1B. A series of novel 3-aryl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene derivatives were designed, synthesized, and evaluated as a new class of inhibitors against PTP1B. Among them, compound 6f displayed moderate inhibitory activity with IC50 of 2.87 ± 0.24 μm and can be used as a novel lead compound for the design of inhibitors of PTP1B.